Medicines labeled for the same conditions

Alternatives to encorafenib

6 other medicines are given the same way (oral) and in the same FDA class as encorafenib or labeled mainly for the same use (colorectal cancer); the others include 1 nucleoside metabolic inhibitor, 1 thymidine phosphorylase inhibitor and 1 kinase inhibitor (FDA labels read October 8, 2026).

Which medicines are labeled for the same conditions as encorafenib?

Colorectal cancer lists all 23 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.

Medicine and FDA class	Shared indication	Generic labelers (oral)	Pharmacy cost	Boxed warning	Shortage
Encorafenib	this medicine	none listed	n/a	No	No current entry
Capecitabinenucleoside metabolic inhibitor	Colorectal cancer	18 labelers	$0.456 per tablet 500 mg tablet	Yes	No current entry
Sotorasib	Lung cancer, Colorectal cancer	none listed	n/a	No	No current entry
Fruquintinib	Colorectal cancer	none listed	n/a	No	No current entry
Tipiracil and trifluridinethymidine phosphorylase inhibitor	Colorectal cancer	none listed	n/a	No	No current entry
Adagrasib	Lung cancer, Colorectal cancer	none listed	n/a	No	No current entry
Regorafenibkinase inhibitor	Colorectal cancer	none listed	n/a	Yes	No current entry

Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)

What do pharmacies pay for each?

The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.

Capecitabine$0.456

Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price

What next?

Encorafenib: the full record: label, generics, price, shortages, recalls